{"F": {"ts_code": "HK.02561", "name": "维昇药业-B", "mkt": "HK", "ccy": "港元", "sw1": "生物技术", "sw2": "生物技术", "sw3": "", "ind": "生物技术", "fin_source": "futu", "market": "主板", "list_date": "20250321", "is_fin": false, "roles": {"fin": false, "commodity": false, "precious": false, "regulated": false, "hard": false, "growth": true}, "province": null, "main_business": "", "introduction": "", "close": 19.68, "pe_ttm": -8.118, "pb": 2.896, "dv_ttm": 0.0, "total_mv": 223866.620352, "trade_date": "20260904", "years": ["最近年报"], "multi_year": false, "period": "最近年报", "gm_series": [11.5], "rev_series": [0.0], "np_series": [-2.8], "roe_series": [-50.8], "rev_ttm": 0.0, "np_ttm": -2.7, "ocf_ttm": -5.2, "fcf_ttm": null, "fcf_yield": null, "ocf_yield": -23.1, "gm_median": 11.5, "gm_std": null, "gm_stab": null, "gm_chg_2022": null, "npm_median": -153589.1, "roe_median": -50.8, "commodity": false, "hard_ratio": 0.1, "fix_assets": 0.0, "goodwill_ratio": null, "pb_calc": null, "capex_dep": null, "interest_debt": null, "debt_ebitda": null, "ebitda": -2.8, "debt_ratio": 22.0, "debt_mv": null, "payout": null, "div_years": 0, "rev_cagr3": null, "np_cagr3": null, "rev_yoy": 0.0, "np_yoy": -45.4, "np_vol": null, "loss_years": 1, "far_share": 100, "earn_yield": null, "consensus_n": 0, "fwd_pe": null, "fwd_pe2": null, "fwd_g1": null, "fwd_g2": null, "peg": null, "consensus_disp": null, "mainbz": [], "ret_prev_year": null, "ret_prev2_year": null, "ret_pivot": null, "prev_year": "", "prev2_year": "", "ret_ytd": -40.0, "ret_20": -0.3, "ret_60": -3.0, "ret_120": -38.5, "ret_250": -56.4, "mdd_250": null, "vol_250": null, "pos_52w": 41.8, "eps": -2.467}, "S": {"duration": 100, "pricing": 38, "hard": 0, "bondness": 13}, "label": "亏损或困境", "tags": [], "text": {"像什么": ["TTM 归母净利 -2.7 亿;PE 为负,估值指标失真。", "资产负债率 22%,有息负债 —,经营现金流/市值 -23.1%:先看现金流能否覆盖利息,再谈久期。"], "为什么(不)算钱的替代品": "两条都不占:固定资产占比 0%,毛利率最新年报 11.5%。", "加息期怎么走": "利率上行对高杠杆亏损企业是再融资压力,不是估值问题;周期底部的反转看行业价格,不看贴现率。", "四问": [["当前 FCF 能覆盖多少市值?", "经营现金流/市值 -23.1%(futu 无资本开支,FCF 按经营现金流 × 0.7 近似)。极低或为负。"], ["能否每年提价而不掉量?", "毛利率最新年报 11.5%。不能。"], ["资产重置成本随通胀涨吗?", "固定资产占总资产 0%。没有资产可言。"], ["估值里多少来自 5 年后的故事?", "按 PE 为负 粗算,约 100%(1 − 5/PE)。>70%,把 5 年后的假设砍一半,这个股票值多少钱?"]], "价格行为": "近一年 -56%,现价在 52 周高点的 42%;近 20 / 60 / 120 日 -0% / -3% / -38%。", "行业对照": ["同富途行业「生物技术」83 家中位:PE 24.1 / 股息率 0.0% / 毛利率 71.7% / 固定资产占比 15% / 分红率 0%。", "维昇药业-B:PE 比行业中位低 32.2倍;股息率 与行业中位持平;毛利率 比行业中位低 60.2个百分点;固定资产占比 比行业中位低 14.5个百分点。"]}}